FDA grants cabozantinib Priority Review for thyroid cancer

FDA accepted and granted Priority Review to an NDA from Exelixis Inc. (NASDAQ:EXEL) for cabozantinib to treat progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC). ...